Transl Clin Pharmacol.
2022 Jun;30(2):71-74. 10.12793/tcp.2022.30.e9.
FDA initiatives to support dose optimization in oncology drug development: the less may be the better
- Affiliations
-
- 1Medirama, Seoul 06927, Korea
- KMID: 2538867
- DOI: http://doi.org/10.12793/tcp.2022.30.e9
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Lessons from US FDA's COVID-19 Related Post-Marketing Drug Safety Monitoring and Evaluation Activities
- Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels
- Suggestions for Radiopharmaceutical Drug Development in Korea Focusing on FDA Exploratory IND Guideline
- A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology
- Comparative Study of First-in-Human Dose Estimation Approaches using Pharmacometrics
